Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial

Background: Although biliary tract cancer (BTC) has a very aggressive nature, some patients maintain a relatively good performance status after failure with first-line treatment of gemcitabine plus cisplatin (GC). Thus, tolerable, feasible, and useful second-line treatments are needed for these pati...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Cancer
Главные авторы: Kim, Seung Tae, Oh, Sung Yong, Lee, Jeeyun, Kang, Jung Hun, Lee, Hyun Woo, Lee, Myung Ah, Sohn, Byeong Seok, Hong, Ji Hyong, Park, Young Suk, Park, Joon Oh, Lim, Ho Yeong
Формат: Artigo
Язык:Inglês
Опубликовано: Ivyspring International Publisher 2019
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856733/
https://ncbi.nlm.nih.gov/pubmed/31772650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.37610
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы